Attached files
file | filename |
---|---|
EX-99.2 - RESIGNATION LETTER - Medite Cancer Diagnostics, Inc. | ex99-2.htm |
EX-99.1 - RESIGNATION LETTER - Medite Cancer Diagnostics, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported)
|
January 17,
2018
|
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
333-143570
|
36-4296006
|
(Commission File
Number)
|
(IRS
Employer Identification No.)
|
4203 SW 34th St.
|
|
Orlando, FL
|
32811
|
(Address of
Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers
On January 17, 2018, the
Board of Directors (the “Board”) of MEDITE Cancer
Diagnostics, Inc. (the “Company”) accepted the
resignations of Michael E. Ott and Michaela Ott from the position
of Directors of the Company effective immediately.
Item
9.01
Financial Statements and
Exhibits
Exhibit
No.
Description
Resignation Letter
of Michael E. Ott
Resignation Letter
of Michaela Ott
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
|
Date:
January 17, 2018
|
By:
|
/s/ Stephen Von Rump
|
|
|
Stephen
Von Rump
|
|
|
Chief
Executive Officer
|
|